Literature DB >> 4365243

Benefit from adrenocorticotrophin in myasthenia gravis.

L A Liversedge, G M Yuill, I M Wilkinson, J A Hughes.   

Abstract

Twenty-one of 29 patients suffering from myasthenia gravis derived benefit from a short intensive course of adrenocorticotrophin (ACTH). The mean duration of benefit was approximately six months. The best results were obtained in patients with a short history of myasthenia. Transient deterioration during the course of injections was encountered in some cases but necessitated assisted respiration only in patients with severe generalized weakness before treatment.

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4365243      PMCID： PMC494671          DOI： 10.1136/jnnp.37.4.412

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  10 in total

1.  The place of corticotropin in the treatment of myasthenia gravis.

Authors:  L D FREYDBERG
Journal:  Ann Intern Med       Date:  1960-04       Impact factor: 25.391

2.  Effect of adrenocorticotropic hormone (ACTH) and cortisone administration in patients with myasthenia gravis and report of onset of myasthenia gravis during prolonged cortisone administration.

Authors:  D GROB; A M HARVEY
Journal:  Bull Johns Hopkins Hosp       Date:  1952-08

3.  Effects of administration of the adrenocorticotropic hormone on patients with myasthenia gravis.

Authors:  C TORDA; H G WOLFF
Journal:  AMA Arch Neurol Psychiatry       Date:  1951-08

4.  Corticosteroids in management of severe, generalized myasthenia gravis. Effectiveness and comparison with corticotropin therapy.

Authors:  N G Brunner; T Namba; D Grob
Journal:  Neurology       Date:  1972-06       Impact factor: 9.910

5.  Corticotropin therapy in myasthenia gravis: effects, indications, and limitations.

Authors:  T Namba; N G Brunner; M S Shapiro; D Grob
Journal:  Neurology       Date:  1971-10       Impact factor: 9.910

6.  Short-term intensive corticotrophin treatment in myasthenia gravis.

Authors:  L A Liversedge
Journal:  Proc R Soc Med       Date:  1971-05

7.  Studies in myasthenia gravis. Short-term massive corticotropin therapy.

Authors:  K E Osserman; G Genkins
Journal:  JAMA       Date:  1966-11-14       Impact factor: 56.272

8.  Results with ACTH and spironolactone in severe cases of myasthenia gravis.

Authors:  G von Reis; A Liljestrand; G Matell
Journal:  Acta Neurol Scand Suppl       Date:  1965

9.  Treatment of myasthenia gravis with adrenocorticotropic hormone (ACTH): massive short-term and maintenance treatment.

Authors:  C A Cape; R A Utterback
Journal:  J Neurol Neurosurg Psychiatry       Date:  1969-08       Impact factor: 10.154

10.  Treatment of ocular myasthenia with corticotrophin.

Authors:  F B Gibberd; F Navab; C L Smith
Journal:  J Neurol Neurosurg Psychiatry       Date:  1971-02       Impact factor: 10.154
  10 in total
  2 in total

1.  Value of exchangeable electrolyte measurement in the treatment of myasthenia gravis.

Authors:  M Critchley; K J Herman; M Harrison; R A Shields; L A Liversedge
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-03       Impact factor: 10.154

2.  A case of myasthenia gravis treated with steroids: some suggestions for the mechanisms underlying their effect.

Authors:  P Dandona; E J Corkan; G E Sladen
Journal:  Postgrad Med J       Date:  1977-06       Impact factor: 2.401
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.